Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Treos Bio Announces $14 Million Convertible Loan Note Financing
Details : Proceeds will fund Phase II clinical trials of PolyPEPI-1018, the Company’s off-the-shelf polypeptide immunotherapy for metastatic colorectal cancer.
Product Name : PolyPEPI-1018
Product Type : Peptide
Upfront Cash : Undisclosed
March 31, 2021
Lead Product(s) : PolyPEPI-SCoV-2 Peptide Vaccine,Montanide ISA 51VG
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PolyPEPI-SCoV-2 vaccine administered with Montanide ISA 51VG adjuvant was safe in two mouse models and elicited highly specific, TH1-biased CD8+ and CD4+ T cell responses against all four structural proteins of the virus.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 19, 2020
Lead Product(s) : PolyPEPI-SCoV-2 Peptide Vaccine,Montanide ISA 51VG
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PolyPEPI-SCoV-2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Treos Bio Forms New Subsidiary to Develop a Preventive COVID-19 Peptide Vaccine
Details : Treos Bio has developed and successfully tested in silico a preventive COVID-19 peptide vaccine and has transferred all rights, including pending patent applications, to a newly formed subsidiary, PepTC Vaccines Limited.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 15, 2020
Lead Product(s) : PolyPEPI-SCoV-2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PolyPEPI1018
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Treos plans to conduct a randomized Phase II study of PolyPEPI1018 in maintenance therapy setting for first-line treatment of MSS mCRC, as well as a Phase I/II study in late-stage patients as an add-on to third-line therapy.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
May 29, 2020
Lead Product(s) : PolyPEPI1018
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable